Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How

Tempus AI's Q3 2025 update highlights accelerating high-margin Data & Services adoption with revenues of $81.3M (up 26.1% YoY) and Insights bookings of $150M, as Insights revenue grew 37.6% YoY. The company bolstered its data and AI position via the acquisition of Paige and a Northwestern Medicine integration for its David generative-AI co-pilot, while expanding Tempus Next into breast cancer; shares have outperformed peers (+10% YTD vs industry -4.1%) but the stock trades at a premium (forward P/S 8.18x vs industry 5.81x) and 2025 loss-per-share estimates have narrowed modestly.

Analysis

Market structure: Tempus (TEM) and adjacent AI/oncology data providers are positioned to capture higher-margin recurring revenue, improving gross margin leverage and giving TEM asymmetric pricing power versus legacy pathology vendors; semiconductor suppliers (NVDA) remain indirect beneficiaries through GPU demand. Expect modest margin expansion over 2-6 quarters if bookings convert, but premium multiples imply investor patience — a >15% miss in conversion would compress peer valuations rapidly.

Risk assessment: Key tail risks are regulatory/privacy interventions (HIPAA/FTC) or a high-profile model error that triggers liability; assign a 5-15% probability over 12 months with outsized downside. Near term (days-weeks) equity sensitivity will hinge on upcoming quarters and integration milestones; medium-term (3-12 months) risks include reimbursement pushback and data access dependency on large health systems.

Trade implications: Favor a controlled long exposure to TEM (equity or spreads) sized 1.5-3% of portfolio with hedges; use NVDA (1-2% long) as a leveraged thematic proxy. Consider a relative-value trade: long TEM vs short a legacy diagnostics/low-AI-growth healthcare name (size 1%), and implement 3-6 month call spreads on TEM (buy ATM, sell 25-35% OTM) to cap premium while keeping upside.

Contrarian angles: Consensus may underweight execution and conversion risk — premium multiple can unwind quickly if bookings-to-revenue conversion falls below 60% over two consecutive quarters. Historical SaaS/healthtech re-ratings suggest set stop-loss triggers (e.g., -12% from entry) and watch two data thresholds: sequential bookings growth and payor reimbursement signals within 90 days.

Key Decisions for Investors

• Establish a 2% long position in TEM via equity or buy a 3-6 month call spread (buy ATM, sell 25-35% OTM) ahead of the next quarterly results; size to risk no more than 0.5% portfolio drawdown and take profits at +25-30% or cut at -12%.
• Add a 1-2% long position in NVDA as a thematic lever to AI infrastructure demand; rebalance if NVDA outperforms TEM by >40% or implied vol spikes >30% (IV >30%).
• Enter a pair trade: long TEM (1.5%) vs short a legacy diagnostics name (1%) — unwind if TEM bookings conversion rate reported over two quarters falls below 60% or TEM sequential bookings growth decelerates by >500 bps.
• Use a defensive options sleeve: sell 6-8 week covered calls on TEM after a >10% rally to monetize premium, or sell 1-2% notional of OTM puts (3-6 month) only if willing to own additional shares with a 10-12% discounted effective entry.
• Trigger-based action: if within 90 days there is an adverse regulatory or major integration announcement (Paige/Northwestern) or payor denial, reduce TEM exposure to 0.5% and redeploy to cash/short-duration credit; if two consecutive quarters show bookings-to-revenue conversion >70% and margins expand >200 bps, increase TEM to 3%.